The prevalence of OP increases with the ageing of the population and is associated with an increased risk of fracture and chronic pain, and the targeting of NGF with chelating antibodies ameliorates musculoskeletal pain including back pain and arthritis (Suzuki et al., 2018). This evidence concerns the gene NGF and arthritic joint disease.